HeartFlow Director Jeffrey Lightcap Acquires 40,000 Shares for $1.05 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 28 2025
0mins
Source: NASDAQ.COM
- Share Acquisition: Director Jeffrey Lightcap purchased 40,000 shares at $26.34 each on December 16, 2025, totaling $1.05 million, increasing his direct holdings to 0.0470%, indicating his confidence in the company's future prospects.
- Indirect Holdings: Lightcap maintains 6.7 million shares indirectly through three affiliated entities, suggesting a diversified investment strategy despite the increase in direct ownership, which still remains largely fund-controlled.
- Market Reaction: This acquisition occurred after the stock hit a 52-week low of $25.38, indicating that Lightcap perceives the current price as attractive, which may positively influence market sentiment.
- Financial Performance: HeartFlow reported $46.3 million in Q3 sales, a 41% year-over-year increase, although it faced a net loss of $50.9 million; however, the forecast for 2025 suggests a 38% revenue growth to approximately $173 million, highlighting the company's growth potential amidst challenges.
Analyst Views on HTFL
Wall Street analysts forecast HTFL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HTFL is 38.60 USD with a low forecast of 35.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 34.980
Low
35.00
Averages
38.60
High
40.00
Current: 34.980
Low
35.00
Averages
38.60
High
40.00
About HTFL
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
